Although there seems to be some promise for the future, at this point, I think theres too much uncertainty and unnecessary risk involved
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Some GLP-1s (e.g., Zepbound) are being studied or already approved for non-weight-loss uses like this
J Transl Med 23(1):427 Chen KS, Koubek EJ, Sakowski SA, Feldman EL (2024) Stem cell therapeutics and gene therapy for neurologic disorders
A Life klinik protokollerimizde, "ya yakc" sreleri sadece estetik bir hedef olarak deil, srdrlebilir bir yaam kalitesi art olarak konumluyoruz
Toward a personalized chronotherapy of blood pressure